
    
      in the GEM- IRE group, before the IRE ablation started, patients received 1000 mg/m2
      gemcitabine hydrochloride [Qilu pharmaceutical (Hainan) Co., Ltd. Haikou, China]
      intravenously (over approximately 30 min).

      In the IRE group, the IRE ablation was performed without gemcitabine intravenous infusion
      before IRE.

      The aim of this study was to evslusted the overall survival (OS), objective response rate
      (ORR) and adverse events after simultaneous therapy.
    
  